Skip to main content
Loading

a:head bio AG

Tuesday, February 27, 2024
Plymouth
CNS/Neurological
Finding new therapies for brain diseases requires preclinical models and assays with increased clinical relevance. a:head aims to develop a human-based platform for generating complex brain-like tissue and analyzing neuronal network activity. Brain organoids are a biomedical revolution representing the most advanced in vitro experimental model of human brain. These 3D cultures mimic the structure and function of the brain with the promise of scalability to enable high-throughput screening of patient neural networks. We are developing a next-generation brain organoid-based drug discovery engine.
Speakers
Joshua Bagley, CSO - a:head bio AG

Country

Austria

Website

http://www.aheadbio.com

CEO/Top Company Official

Oliver Szolar

Lead Product in Development

brain organoid screening platform

Development Phase of Primary Product

Discovery
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Media Partner


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP